Your CIRS Symptoms Persist Despite Avoiding Mold. Here's the Biological Reason.

The GSTM1 gene produces an enzyme that does critical work in phase II detoxification. In phase II, your liver takes toxins that were made water-soluble in phase I and attaches them to glutathione molecules so they can be safely excreted. GSTM1 specializes in conjugating mycotoxins, pesticides, and other environmental electrophiles so your body can eliminate them.

Roughly 50% of people carry a complete deletion of this gene, called the GSTM1 null genotype. When you have this deletion, you’re missing the entire GSTM1 enzyme. Your capacity to eliminate mycotoxins and many environmental toxins drops dramatically, leaving these compounds circulating longer in your bloodstream and tissues. This doesn’t mean you can’t handle toxins at all, but your margin for error is much narrower.

If you have the GSTM1 null variant and get exposed to mold, the mycotoxins linger in your system longer. Your immune system stays activated trying to clear what your detox system can’t efficiently eliminate. The inflammation becomes chronic. You develop brain fog, joint pain, fatigue, and respiratory symptoms that persist even after you’ve left the contaminated environment.

GSTP1 is another phase II detoxification enzyme, but it specializes in a different job. While GSTM1 handles some mycotoxins and electrophiles, GSTP1 focuses on detoxifying reactive oxygen species and the byproducts of oxidative stress that accumulate from inflammatory exposures. It also handles a range of environmental pollutants and pesticides.

The Val105 variant of GSTP1, carried by roughly 35 to 40% of people, produces an enzyme with reduced activity compared to the wild-type. Your cells generate reactive oxygen molecules faster than your GSTP1 can neutralize them, so oxidative stress accumulates in your tissues and bloodstream. This becomes particularly problematic after mold exposure because mold triggers a massive inflammatory cascade that generates reactive oxygen species as a byproduct.

With a compromised GSTP1 variant, you don’t just have trouble eliminating mycotoxins. You also struggle to handle the oxidative stress that the immune response itself generates. You end up in a vicious cycle: inflammation triggers oxidative stress, oxidative stress can’t be cleared efficiently, which triggers more inflammation. This explains why some CIRS patients feel worse even in a clean environment if their antioxidant genes are weak.

SOD2 is an antioxidant enzyme that works specifically inside your mitochondria, the energy factories of your cells. Mitochondria generate energy through a process that naturally produces reactive oxygen species as a byproduct. SOD2 keeps these free radicals in check so they don’t damage the mitochondrial machinery itself. When your mitochondria stay healthy, your cells produce energy efficiently and your immune system functions properly.

The Ala16 variant of SOD2, present in roughly 40% of people with European ancestry in homozygous form, produces less efficient enzyme. When you’re exposed to mycotoxins or environmental toxins, your mitochondria are forced to work harder to detoxify and clear the burden, which generates even more reactive oxygen species that SOD2 can’t adequately neutralize. Your mitochondrial DNA itself becomes damaged, and your cells lose their ability to produce energy efficiently.

This explains a cardinal symptom of CIRS: crushing fatigue that doesn’t respond to sleep. Your mitochondria are under oxidative siege. Even if you rest, your cells can’t generate the ATP energy currency they need. You feel exhausted at a cellular level because you literally are. Your energy-producing machinery is struggling against a tide of oxidative stress.

MTHFR converts folate into methylfolate, the active form your body uses to run the methylation cycle. The methylation cycle does hundreds of jobs, but one of the most critical for CIRS recovery is producing glutathione, your master antioxidant. When methylation works properly, you produce adequate glutathione to handle oxidative stress and support phase II detoxification. You also produce adequate SAMe and other methyl donors that support liver regeneration and immune regulation.

The C677T variant of MTHFR, carried by roughly 40% of people with European ancestry, reduces enzyme efficiency by 35 to 40%. Your cells produce less methylfolate, which means your methylation cycle runs slower, which means you produce less glutathione even if you eat plenty of folate and B vitamins. You’re functionally depleted at the biochemical level, even though your standard bloodwork looks normal.

In CIRS, this becomes a compounding problem. You’re exposed to mycotoxins, which demand more glutathione for detoxification. But your MTHFR variant means you produce less glutathione even under normal circumstances. You enter CIRS with a pre-existing deficit. The mycotoxins deplete whatever glutathione you do have, and your body can’t regenerate it fast enough. You’re stuck in a glutathione-depleted state, which makes the inflammation worse and the detoxification slower.

TNF is a cytokine, a chemical messenger that orchestrates the inflammatory response. When you encounter a pathogen or a toxin, your immune system releases TNF to activate the inflammatory cascade that kills the threat and clears the damage. But TNF also needs to be tightly regulated. If TNF stays elevated too long, inflammation becomes chronic and pathological.

The A allele of the TNF -308G>A variant, carried by roughly 30% of people, is associated with higher TNF production in response to environmental triggers. When you’re exposed to mycotoxins, your TNF levels spike higher and stay elevated longer than they do in people with the G allele, driving a more intense and persistent inflammatory response. Your immune system treats the mycotoxin exposure as a massive threat and mounts a disproportionate reaction.

This is why some CIRS patients develop such severe systemic symptoms from what seems like a brief or limited mold exposure. It’s not that their exposure was worse. It’s that their TNF response genes make them mount a more aggressive inflammatory cascade. Once that cascade is triggered, it can take months or years to calm down, especially if other detoxification or antioxidant genes are also compromised. The inflammation becomes self-perpetuating.

HLA genes encode proteins that sit on the surface of your immune cells and present antigens (foreign molecules) to your T cells so they can be recognized as threats or non-threats. HLA-DQ2 is particularly important in how your immune system recognizes and responds to mold antigens and certain proteins in food. It also influences whether your body develops a cross-reactive response where exposure to one mold species triggers recognition of similar proteins in foods.

HLA-DQ2 is not rare; it’s present in roughly 30 to 35% of people, particularly those with European ancestry. If you carry HLA-DQ2, your immune system is primed to mount a strong response to mold antigens, but it also tends to cross-react with certain foods, especially grains and processed foods containing mold-related proteins. This is why many CIRS patients notice that removing grains dramatically improves their symptoms, even though they don’t have celiac disease.

HLA-DQ2 also influences your susceptibility to developing mold-triggered autoimmune responses. Instead of just clearing the mold and returning to normal immune function, your immune system can get locked into a pattern of attacking your own tissues if those tissues express epitopes (molecular patterns) that resemble the mold antigens. This is part of why CIRS can persist even after successful mold avoidance.